Related Experiment Video

Updated: May 15, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

[T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]

Emi Noguchi1, Chikako Shimizu

  • 1Division of Breast and Medical Oncology, National Cancer Center Hospital, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 12, 2013
PubMed

Insights

New anti-HER2 agents, T-DM1 and pertuzumab, show promise in late-phase clinical trials for HER2-positive breast cancer. These advancements build upon the success of earlier therapies like trastuzumab.

Area of Science:

  • Oncology
  • Medical Science
  • Pharmacology

Background:

  • HER2-positive breast cancer therapy has seen significant progress.
  • Trastuzumab, a monoclonal antibody, was the first HER2-targeted therapy.
  • Lapatinib, a tyrosine kinase inhibitor, represents a subsequent development in HER2-targeted agents.

Purpose of the Study:

  • To describe the results of late-phase clinical trials.
  • To evaluate two newly available anti-HER2 agents: T-DM1 and pertuzumab.

Main Methods:

  • Late-phase clinical trials were conducted.
  • The efficacy and safety of T-DM1 and pertuzumab were assessed.

Main Results:

  • Results from late-phase clinical trials are presented.
  • The study focuses on the performance of T-DM1 and pertuzumab.

Conclusions:

  • T-DM1 and pertuzumab are newly available anti-HER2 agents.
  • These agents are part of ongoing advancements in HER2-positive breast cancer treatment.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...